Litcius/Paper detail

A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinoma

David C. Smith, Matthias Kroiß, Electron Kebebew, Mouhammed Amir Habra, Rashmi Chugh, Bryan J. Schneider, Martin Faßnacht, Pegah Jafarinasabian, M. Marian Ijzerman, Vivian Lin, Pharis Mohideen, Aung Naing

2020Investigational New Drugs57 citationsDOI

Topics & Concepts

MedicineAdrenocortical carcinomaMitotaneGastroenterologyInternal medicineVomitingAdverse effectResponse Evaluation Criteria in Solid TumorsAdrenal insufficiencyChemotherapyPhases of clinical researchEndocrinologyPharmacologyAdrenal and Paraganglionic TumorsHormonal Regulation and HypertensionCancer, Hypoxia, and Metabolism
A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinoma | Litcius